In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01156-9
Abstract: Background Entrectinib is a CNS-active, potent inhibitor of tyrosine receptor kinases A/B/C, ROS1 and anaplastic lymphoma kinase approved for use in patients with solid tumors. We describe the in vitro and clinical studies investigating potential… read more here.
Keywords: inhibitor; entrectinib; vitro clinical; drug ... See more keywords
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100072
Abstract: Background Entrectinib is a tropomyosin receptor kinase inhibitor approved for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours based on single-arm trials. Traditional randomised clinical trials in rare cancers are not feasible;… read more here.
Keywords: entrectinib; analysis; prior therapy; single arm ... See more keywords
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa052
Abstract: Abstract Background Studies evaluating the CNS penetration of a novel tyrosine kinase inhibitor, entrectinib, proved challenging, particularly due to discrepancies across earlier experiments regarding P-glycoprotein (P-gp) interaction and brain distribution. To address this question, we… read more here.
Keywords: inhibitor; entrectinib; crizotinib larotrectinib; interaction ... See more keywords